325 related articles for article (PubMed ID: 38374366)
1. The changing landscape of thyroid eye disease: current clinical advances and future outlook.
Moledina M; Damato EM; Lee V
Eye (Lond); 2024 Jun; 38(8):1425-1437. PubMed ID: 38374366
[TBL] [Abstract][Full Text] [Related]
2. Teprotumumab and the Evolving Therapeutic Landscape in Thyroid Eye Disease.
Kossler AL; Douglas R; Dosiou C
J Clin Endocrinol Metab; 2022 Aug; 107(Suppl_1):S36-S46. PubMed ID: 36346685
[TBL] [Abstract][Full Text] [Related]
3. Socioeconomic Disparities in the Presentation and Treatment of Graves' Disease and Thyroid Eye Disease.
Vargason CW; Chelnis JG; Barahimi BI; Mawn LA
Semin Ophthalmol; 2016; 31(4):409-14. PubMed ID: 27385363
[TBL] [Abstract][Full Text] [Related]
4. Future Projections in Thyroid Eye Disease.
Barbesino G; Salvi M; Freitag SK
J Clin Endocrinol Metab; 2022 Aug; 107(Suppl_1):S47-S56. PubMed ID: 36346684
[TBL] [Abstract][Full Text] [Related]
5. Clinical Management and Therapeutic Strategies for the Thyroid-Associated Ophthalmopathy: Current and Future Perspectives.
Mishra S; Maurya VK; Kumar S; Ankita ; Kaur A; Saxena SK
Curr Eye Res; 2020 Nov; 45(11):1325-1341. PubMed ID: 32567373
[TBL] [Abstract][Full Text] [Related]
6. Teprotumumab: Interpreting the Clinical Trials in the Context of Thyroid Eye Disease Pathogenesis and Current Therapies.
Winn BJ; Kersten RC
Ophthalmology; 2021 Nov; 128(11):1627-1651. PubMed ID: 33930408
[TBL] [Abstract][Full Text] [Related]
7. Graves' ophthalmopathy: the clinical and psychosocial outcomes of different medical interventions - a systematic review.
Bello OM; Druce M; Ansari E
BMJ Open Ophthalmol; 2024 Jun; 9(1):. PubMed ID: 38886120
[TBL] [Abstract][Full Text] [Related]
8. Tocilizumab for thyroid eye disease.
Hamed Azzam S; Kang S; Salvi M; Ezra DG
Cochrane Database Syst Rev; 2018 Nov; 11(11):CD012984. PubMed ID: 30480323
[TBL] [Abstract][Full Text] [Related]
9. Knowledge of Thyroid Eye Disease in Graves' Disease Patients With and Without Orbitopathy.
Edmunds MR; Boelaert K
Thyroid; 2019 Apr; 29(4):557-562. PubMed ID: 30688164
[TBL] [Abstract][Full Text] [Related]
10. Current and Emerging Treatment Strategies for Graves' Orbitopathy.
Genere N; Stan MN
Drugs; 2019 Feb; 79(2):109-124. PubMed ID: 30659423
[TBL] [Abstract][Full Text] [Related]
11. A Paradigm Shift in the Management of Thyroid Eye Disease How Teprotumumab Has Changed the Therapeutic Interface.
Ugradar S; Kossler AL; Douglas R; Cockerham K
J Neuroophthalmol; 2022 Mar; 42(1):26-34. PubMed ID: 35500236
[TBL] [Abstract][Full Text] [Related]
12. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
13. A Review of Novel Medical Treatments for Thyroid Eye Disease.
Park JW; Yoon JS
Korean J Ophthalmol; 2024 Jun; 38(3):249-259. PubMed ID: 38773958
[TBL] [Abstract][Full Text] [Related]
14. A 'Real Life' Service Evaluation Model for Multidisciplinary Thyroid Eye Services.
Farag S; Feeney C; Lee V; Nagendran S; Jain R; Aziz A; Akishar R; Bravis V; Meeran K
Front Endocrinol (Lausanne); 2021; 12():669871. PubMed ID: 34025584
[TBL] [Abstract][Full Text] [Related]
15. Understanding the clinical and molecular basis of thyroid orbitopathy: a review of recent evidence.
Nivean PD; Madhivanan N; Kumaramanikavel G; Berendschot TTJM; Webers CAB; Paridaens D
Hormones (Athens); 2024 Mar; 23(1):25-34. PubMed ID: 37910311
[TBL] [Abstract][Full Text] [Related]
16. Understanding Pathogenesis Intersects With Effective Treatment for Thyroid Eye Disease.
Smith TJ
J Clin Endocrinol Metab; 2022 Aug; 107(Suppl_1):S13-S26. PubMed ID: 36346686
[TBL] [Abstract][Full Text] [Related]
17. The eye and thyroid disease.
Kuriyan AE; Phipps RP; Feldon SE
Curr Opin Ophthalmol; 2008 Nov; 19(6):499-506. PubMed ID: 18854695
[TBL] [Abstract][Full Text] [Related]
18. Updates on the understanding and management of thyroid eye disease.
Men CJ; Kossler AL; Wester ST
Ther Adv Ophthalmol; 2021; 13():25158414211027760. PubMed ID: 34263138
[TBL] [Abstract][Full Text] [Related]
19. [Graves' orbitopathy].
Eckstein A; Möller L; Führer D; Oeverhaus M
Dtsch Med Wochenschr; 2021 Oct; 146(20):1344-1351. PubMed ID: 34644795
[TBL] [Abstract][Full Text] [Related]
20. Treatment of moderate to severe orbitopathy: Current modalities and perspectives.
Bouzehouane N; Borson-Chazot F; Abeillon J; Caron P
Ann Endocrinol (Paris); 2021 Apr; 82(2):92-98. PubMed ID: 33676921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
